Evidence of androgenetic alopecia, or male pattern baldness, can be distressing for transgender women. Here we present the case of a transgender woman with scalp hair regrowth after ∼6 months on oral estradiol and spironolactone therapy achieving testosterone levels within normal female range.
Get full access to this article
View all access options for this article.
References
1.
BanksN, BunaganMJK, ShapiroJ. Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin. 2013; 31:129–140.
2.
EllisJA, SinclairRD. Male pattern baldness: current treatments, future prospects. Drug Discov Today. 2008; 13:791–797.
3.
HaberRS. Pharmacologic management of pattern hair loss. Facial Plast Surg Clin North Am. 2004; 12:181–189.
4.
FinnDA, et al.A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006; 12:53–76.
5.
DrakeL, HordinskyM, FiedlerV, et al.The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999; 41:550–554.
6.
GooreenL. Care of transsexual persons. N Engl J Med. 2011; 364:1251–1257.
7.
MeriggiolaMC, GavaG. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. Clin Endocrinol., 2015; 83:607–615.
8.
FortnerKB, LipariCW. Hyperandrogenism. In: The Johns Hopkins Manual of Gynecology and Obstetrics, 3rd ed. (FortnerKB, SzymanskiLM, FoxHE, WallachEE; eds). Baltimore, ML: Lippincott Williams & Wilkins, 2007, pp. 428–435.
9.
PriorJC, VignaYM, WatsonD. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989; 18:49–57.
10.
SinclairRD, DawberRPR. Androgenetic alopecia in men and women. Clin Dermatol. 2001; 19:167–178.
11.
SantenRJ. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men?. J Clin Invest. 1975; 56:155–5.
